Eupraxia Pharmaceuticals (EPRX) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Eupraxia Pharmaceuticals is set to announce its quarterly earnings on August 6th, expecting to report earnings of ($0.21) per share.
• Analysts currently maintain a consensus rating of "Buy" for Eupraxia Pharmaceuticals, with an average target price of $11.00.
• Royal Bank of Canada increased its stake in Eupraxia Pharmaceuticals by 21.1%, owning approximately 0.96% of the company after the purchase.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.21) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ:EPRX traded down $0.10 during trading on Friday, hitting $5.30. 4,758 shares of the company's stock were exchanged, compared to its average volume of 11,857. Eupraxia Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $6.20. The firm has a 50-day moving average price of $4.79 and a two-hundred day moving average price of $3.98. The firm has a market cap of $190.73 million, a P/E ratio of -6.98 and a beta of 1.50.

Analyst Upgrades and Downgrades

EPRX has been the subject of several analyst reports. Canaccord Genuity Group assumed coverage on shares of Eupraxia Pharmaceuticals in a research report on Monday, June 16th. They set a "speculative buy" rating for the company. HC Wainwright assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, June 26th. They set a "buy" rating and a $12.00 price objective for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, July 24th. They set an "overweight" rating and a $11.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $11.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Eupraxia Pharmaceuticals stock. Royal Bank of Canada lifted its holdings in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) by 21.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 342,828 shares of the company's stock after purchasing an additional 59,683 shares during the quarter. Royal Bank of Canada owned 0.96% of Eupraxia Pharmaceuticals worth $1,125,000 as of its most recent SEC filing.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.